Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

PHASE1

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The part A of the trial has been completed according to the protocol. The part B has not been opened because of unfeasibility (experimental products not yet available).

Conditions

Advanced Cancer

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Tilsotolimod

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris